...
首页> 外文期刊>Current treatment options in neurology >Treatment Options for Optic Pathway Gliomas
【24h】

Treatment Options for Optic Pathway Gliomas

机译:视神经胶质瘤的治疗选择

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Gliomas that affect the optic pathways are for the most part low-grade neoplasms that often, but not always, have good prognoses. Optimal treatment and management of optic pathway gliomas remains unclear and the decision hinges upon several factors including patient age, tumor location, and visual symptoms. We favor a treatment approach that is dependent on the location of tumor within anterior, chiasmal or posterior/hypothalamic visual pathways. In children who are minimally or not symptomatic, we recommend observation rather than early treatment intervention. Most of these patients will have neurofibromatosis type 1 (NF1) based on the natural history and their pilocytic astrocytoma histology. Serial magnetic resonance imaging studies and formal neuro-ophthalmology testing should enable close observation of these patients, with intervention being reserved for when tumor progression results in significant visual loss or proptosis. Chemotherapy is an accepted first line treatment, and a number of effective medications are available, although no agent has proven clearly superior. If progression is accompanied by the complete loss of vision, surgery can be utilized to help alleviate structural issues (ie, proptosis). Minimally symptomatic chiasmal or hypothalamic tumors that arise in the setting of NF1 can also be observed initially because of their favorable prognosis. Children with NF1 and chiasmal or posterior visual tumors who progress either on imaging or clinical grounds (ie, development of significant visual deficits) should be treated first with chemotherapy rather than radiation therapy to minimize the effects on the developing central nervous system. Individuals without NF1 presenting with a chiasmal or hypothalamic mass are candidates for biopsy to determine the underlying pathology of the lesion. Symptomatic patients with pilocytic astrocytoma should first receive chemotherapy. In contrast, other histologies including malignant optic pathway gliomas should be treated similar to other gliomas that occur in other locations with appropriate doses of radiation and chemotherapy.
机译:影响视神经通路的神经胶质瘤大多数是低度恶性肿瘤,通常但并非总是有良好的预后。视神经胶质瘤的最佳治疗和管理仍不清楚,该决定取决于几个因素,包括患者年龄,肿瘤位置和视觉症状。我们主张一种治疗方法,该方法取决于肿瘤在前,后或后/下丘脑视觉通路中的位置。对于症状轻微或没有症状的儿童,我们建议观察而不是早期治疗干预。这些患者中的大多数根据自然病史和毛细血管星形细胞瘤的组织学特点会患有1型神经纤维瘤病(NF1)。串行磁共振成像研究和正式的神经眼科检查应能够对这些患者进行密切观察,并在肿瘤进展导致明显的视力丧失或眼球突出时保留干预措施。化学疗法是公认的一线治疗方法,尽管没有药物被证明具有明显的优越性,但仍可以使用许多有效的药物。如果进展伴有视力完全丧失,则可以利用手术来缓解结构性问题(即眼球突出)。由于其良好的预后,最初也可观察到在NF1背景下出现的症状轻微的chiasmal或下丘脑肿瘤。患有NF1并伴有影像学或临床原因(即,明显的视力缺陷的发展)而发生的裂口或后视视觉肿瘤的儿童,应首先采用化学疗法而非放射疗法进行治疗,以最大程度地减少对发育中的中枢神经系统的影响。没有NF1并伴有下丘脑或下丘脑包块的个体可进行活检以确定病变的潜在病理。有症状的毛细胞星形细胞瘤患者应首先接受化疗。相反,包括恶性视神经胶质瘤在内的其他组织学应采用适当剂量的放射治疗和化学疗法,与发生在其他部位的其他神经胶质瘤相似地进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号